Cart
sales@molnova.com
L-838417 D9
CAS No. 1213669-91-0
L-838417 D9( CTP354 | C-21191 )
Catalog No. M27542 CAS No. 1213669-91-0
L-838417 is a novel deuterated subtype-selective GABAA positive allosteric modulator, acting as a partial agonist at α2, α3 and α5 subtypes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 53 | In Stock |
|
| 2MG | 29 | In Stock |
|
| 5MG | 44 | In Stock |
|
| 10MG | 65 | In Stock |
|
| 25MG | 130 | In Stock |
|
| 50MG | 207 | In Stock |
|
| 100MG | 333 | In Stock |
|
| 200MG | 462 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameL-838417 D9
-
NoteResearch use only, not for human use.
-
Brief DescriptionL-838417 is a novel deuterated subtype-selective GABAA positive allosteric modulator, acting as a partial agonist at α2, α3 and α5 subtypes.
-
DescriptionL-838417 is a novel deuterated subtype-selective GABAA positive allosteric modulator, acting as a partial agonist at α2, α3 and α5 subtypes.
-
In Vitro——
-
In Vivo——
-
SynonymsCTP354 | C-21191
-
PathwayOthers
-
TargetOther Targets
-
RecptorTFIIH
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1213669-91-0
-
Formula Weight408.45
-
Molecular FormulaC19H19F2N7O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 12.5 mg/mL (30.60 mM)
-
SMILESCN1N=CN=C1COC2=NN3C(C=C2C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=NN=C3C4=CC(F)=CC=C4F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Pinho-Ribeiro FA, et al. Protective effects of the flavonoid hesperidin methyl chalcone in inflammation and pain in mice: role of TRPV1, oxidative stress, cytokines and NF-κB. Chem Biol Interact. 2015 Feb 25;228:88-99.
molnova catalog
related products
-
4-Methylkaempferol
4'-Methylkaempferol
-
Flavanone
Used as organic synthesis and medicine intermediate.
-
5-HT2B antagonist-1
5-HT2B antagonist-1 is an orally active 5-HT2B receptor antagonist with an IC50 of 33.4 nM, suitable for studies of diseases characterized by 5-HT2B receptor signaling, such as hepatocellular carcinoma, cardiovascular disease, or gastrointestinal disease .
